Embla Medical Hf S/Adr (OSSUY) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Embla Medical Hf.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.522 At this time, I would like to welcome everyone to this Q3 2025 00:00:05.522 -- 00:00:08.849 conference call. Today's call is being recorded. 00:00:08.849 -- 00:00:12.797 If you have any objections, please disconnect at this time. 00:00:12.797 -- 00:00:17.586 All participants will be on listen-only mode throughout the presentation, and afterwards 00:00:17.586 -- 00:00:19.960 there will be a question and answer session. 00:00:19.960 -- 00:00:25.189 I would now like to introduce President and CEO Svend Selvason and CFO Anna 00:00:25.189 -- 00:00:26.671 Svendstadir. 00:00:26.671 -- 00:00:28.675 I will now send a call over to your speakers. 00:00:28.675 -- 00:00:31.516 You may now begin your presentation. 00:00:32.702 -- 00:00:37.269 Thank you, operator. And good morning and welcome to the Ampla Medical Conference call 00:00:37.269 -- 00:00:40.996 where we will review the third quarter of 2025. 00:00:40.996 -- 00:00:45.796 I am Svend Selvason, President and CEO of Ampla Medical. 00:00:45.796 -- 00:00:49.680 And joining me on today's call from Copenhagen is our Chief Financial Officer, Artur 00:00:49.680 -- 00:00:54.703 Svensdottir, and Angela Merikos, Head of Investor Relations at Kaussintag. 00:00:54.705 -- 00:00:59.771 The presentation should take approximately 15 minutes, after which there will be an 00:00:59.771 -- 00:01:03.995 opportunity to ask questions during a Q&A session. 00:01:03.995 -- 00:01:08.017 And if you please go to the next slide. 00:01:08.760 -- 00:01:13.585 Sales in the third quarter amounted to 237 million, representing 00:01:13.585 -- 00:01:18.641 7% organic growth, And our reported growth was 11% for 00:01:18.641 -- 00:01:23.807 the quarter, including three percentage point impact from FX and one percentage 00:01...